Category: Emerging Medicine
ACC 2022: Update on Mavacamten for Obstructive Hypertrophic Cardiomyopathy
April 29, 2022Mavacamten had a big week at the American College of Cardiology 2022 Scientific Sessions, with two positive Late-Breaking Clinical Trial sessions. Mavacamten is an investigational, first-in-class, cardiac-specific myosin inhibitor that reduces the number of available actin-myosin cross-bridges and thus decreases excessive myocardial contractility.
ACC 2022: Novel Gene-Silencing Therapy Cuts Lp(a) by 98%
April 11, 2022Among the top-notch research presented at the American College of Cardiology 2022 Scientific Sessions was a small phase 1 trial that demonstrated big potential for a therapeutic that will lower lipoprotein [Lp(a)] and reduce atherosclerotic risk.
FDA Approves Empagliflozin for HFpEF
March 3, 2022FDA Approves Empagliflozin for Heart Failure with Preserved Ejection Fraction. With this latest FDA approval, it’s time to get up to date on the newest treatments for heart failure. K2P is here to help.
How (and Why) to Keep up with Emerging Medicine
September 9, 2020Staying on top of emerging medicine is vital for providing the best care to patients and has multiple benefits for physicians. Staying on top of emerging medicine is vital for providing the best care to patients and has multiple benefits for physicians.
Rethinking Rhythm Control in AF: Sooner Rather than Later?
September 8, 2020One of the several noteworthy trials presented at the virtual ESC Congress was the EAST-AFNET 4NET 4 trial, which was published concurrently in the New England Journal of Medicine.
The Endothelium: A Common Denominator Underlying “Atypical” Manifestations of COVID-19?
June 15, 2020A group of Italian researchers recently hypothesized that it is actually the endothelium that is being targeted by the COVID-19 virus.
The Relationship Between COVID-19 and Stroke
May 15, 2020COVID-19 does not always fit into the pattern of respiratory illness. While initially unexpected, clinicians and researchers are learning more each day that COVID-19 infection wears many disguises. In some victims, it clearly does not make its initial appearance as a respiratory virus.
Heartline “Virtual” Randomized Trial Opens Enrollment
February 24, 2020Atrial Fibrillation: Scope of the Problem The prevalence of atrial fibrillation (AF) in the United States is estimated to rise from ≈5.2 million in 2010 to 12.1 million in 2030.…
Challenges in Cardiovascular Risk Modification: Blood Pressure
February 18, 2020Partnering with patients to assess their risk for cardiovascular disease can be a challenge. Developing a plan of care to manage hypertension is individualized; incorporating patient buy-in sets the stage…
Reducing Cardiovascular Risk in Management of Type-II Diabetes
January 9, 2020The 2019 ACC/AHA Guideline on the Prevention of Cardiovascular Disease includes management of diabetes mellitus as a key takeaway for cardiologists caring for patients with this comorbidity.